UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as
second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
Authors*: Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Francis Powell, Liza Cosca
Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia Ibrahim Jalal, Joseph
Fiore, Joy Yang Ge, Harry Raftopoulos, Leena Gandhi
Abstract #: 9027
Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM
Location: Hall A, Poster Board #350
Poster Session: Lung Cancer - Non-Small Cell Metastatic
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9027)
Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer,
mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare
tumors of the mediastinum. His research involves designing clinical trials to study new compounds and
treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine,
and are actively working to translate laboratory-based findings to the clinic, especially for patients with
epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new
immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of
Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic
Malignancy Interest Group.
http://profiles.ucsf.edu/matthew.gubens
*UCSF authors in bold
14